Recomp Stack

The Recomp Stack targets simultaneous fat loss and muscle preservation through three complementary mechanisms. Tesamorelin, as an FDA-approved GHRH analog, stimulates endogenous GH production which shifts metabolism toward lipolysis and protein synthesis. Clinical trials specifically demonstrated Tesamorelin''s ability to reduce visceral adipose tissue (the metabolically dangerous deep abdominal fat) by 15-20% over 26 weeks without significant loss of lean mass — making it ideal for body recomposition rather than simple weight loss. AOD-9604 is a modified fragment of human growth hormone (amino acids 177-191) with a tyrosine addition. It retains the lipolytic (fat-burning) activity of GH without its growth-promoting or diabetogenic effects. AOD-9604 stimulates lipolysis and inhibits lipogenesis by mimicking the way natural GH regulates fat metabolism. Importantly, it does not affect blood sugar or promote cellular proliferation, making it safer for sustained fat-loss protocols. It received GRAS (Generally Recognized As Safe) status from the FDA for use as a food supplement, though injectable forms remain Category 2. CJC-1295 (no DAC) provides additional pulsatile GH stimulation that amplifies the Tesamorelin effect while maintaining physiological GH patterns. The triple combination creates a metabolic environment where the body preferentially burns fat while preserving and even building lean tissue — true recomposition. Results are optimized when combined with resistance training and moderate caloric deficit (200-300 calories below maintenance). Users should expect gradual rather than dramatic changes: 1-2 lbs of fat loss per week with stable or slightly increasing lean mass over 8-12 week cycles.